Avutometinib plus defactinib granted priority review by FDA, under the accelerated approval pathway, for recurrent KRAS mutant LGSOC; PDUFA action date set for June 30, 2025 Potential U.S. commercial ...
Erasca, Inc. presents promising preclinical data on ERAS-0015 and ERAS-4001 targeting RAS/MAPK pathway cancers at AACR meeting. Erasca, Inc. presented new preclinical data at the American Association ...
Genomic profiling is crucial in metastatic colorectal cancer (CRC) management: RAS and BRAF alterations govern prognosis and eligibility for targeted therapies. The expanding landscape of RAS directed ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results